Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting
October 09 2020 - 7:30AM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
that it will present initial data from the ongoing dose escalation
portion of its Phase 1 clinical trial of SY-5609, its highly
selective and potent oral cyclin-dependent kinase 7 (CDK7)
inhibitor, in patients with select solid tumors. The data will be
presented in a poster session at the 32nd EORTC-NCI-AACR Symposium,
taking place virtually October 24-25, 2020, and will include data
on safety, pharmacokinetics and pharmacodynamics.
The abstract is now available on the EORTC-NCI-AACR conference
website at https://event.eortc.org/ena2020/. The presentation will
be available for on-demand viewing on the ENA website starting
Saturday, Oct. 24, 2020.
Details of the poster presentation are as follows:
Presentation Title: Early evidence of dose-dependent
pharmacodynamic activity following treatment with SY-5609, a highly
selective and potent oral CDK7 inhibitor, in patients with advanced
solid tumors Session Title: New Drugs Presenter:
Kyriakos P. Papadopoulos, M.D., South Texas Accelerated Research
Therapeutics Abstract Number: 180
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust pipeline, including SY-1425, a first-in-class oral selective
RARα agonist in a Phase 2 trial in a genomically defined subset of
acute myeloid leukemia patients, and SY-5609, a highly selective
and potent oral CDK7 inhibitor in a Phase 1 trial in patients with
select solid tumors. Syros also has multiple preclinical and
discovery programs in oncology and monogenic diseases. For more
information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201009005202/en/
Media Contact: Naomi Aoki Syros Pharmaceuticals
617-283-4298 naoki@syros.com
Investor Contact: Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2024 to May 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From May 2023 to May 2024